The Medical Journal of Australia · 1993 · 66 citations · 3 references
MedicineInternal MedicinePharmacotherapyClinical EpidemiologyClinical PharmacologyHepatologyBiliary Tract DisordersCholestatic Liver InjuryLiver DiseaseCholestatic JaundiceCohort Study InvestigationLiver Disease Risk AssessmentRetrospective Case Study
OBJECTIVE: To estimate the risk of cholestatic hepatitis of uncertain origin in patients who had recently received erythromycin, a drug which is known to cause this disorder. DESIGN: A retrospective cohort study using data automatically recorded on general practitioners' office computers. SETTING: Some 600 general practices in the United Kingdom. SUBJECTS: 366,064 people who received erythromycin. MAIN OUTCOME MEASURE: Clinically documented cholestatic hepatitis of uncertain origin diagnosed 1-45 days after a prescription for erythromycin. RESULTS: There were 13 cases of cholestatic hepatitis of uncertain origin diagnosed within 45 days of receiving erythromycin which were either characteristic of or consistent with a syndrome previously described as being associated with this drug. CONCLUSION: The risk of cholestatic jaundice associated with erythromycin is estimated to be in the range of 3.6 per 100,000 users (95% confidence interval, 1.9-6.1).
3
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Robert C. Hastings, Gillis W. Long · JAMA · 1991 · 1.1K citations
Erythromycin estolate and jaundice.
W.H.W. Inman, Nigel S. B. Rawson · BMJ · 1983 · 44 citations · Full text